← All trials
NCT04842201
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2021
- Primary completion
- Sep 28, 2021
- Completion date
- Feb 28, 2022
- First posted
- Apr 13, 2021
- Last posted
- Nov 11, 2021
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Keymed Biosciences Co.LtdLead sponsor
- PKUcare luzhong hospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.